When Legal Access Is Not Enough: Equity Barriers to Medical Cannabis Access—Evidence from Oklahoma’s Medical Cannabis Program

Sheena C. Wilton, MS, MCT
Lake Erie College of Osteopathic Medicine

Background: Medical cannabis legalization has expanded legal eligibility for cannabinoid therapeutics; however, legal access and equitable access are distinct concepts. Oklahoma was selected as the study site because it operates one of the nation’s most accessible medical cannabis programs, providing an opportunity to examine whether broad legal eligibility translates into equitable patient access. Equitable access requires that patients can realistically obtain, afford, and safely utilize cannabinoid therapeutics within healthcare and regulatory systems. Understanding this distinction is essential when evaluating medical cannabis programs serving medically vulnerable populations.

Objective(s): To evaluate the gap between legal access and equitable access within Oklahoma’s medical cannabis program by identifying regulatory and structural barriers affecting medically vulnerable populations despite legal eligibility.

Methods: A qualitative policy evaluation and document analysis were conducted using publicly available Oklahoma Medical Marijuana Authority (OMMA) regulations, licensing and patient data, federal housing guidance, demographic information, peer-reviewed literature, and four semi-structured executive interviews representing regulatory, clinical, laboratory, and vertically integrated industry perspectives. Evidence from these sources was triangulated and synthesized using a comparative policy and health equity framework to identify recurring regulatory, structural, geographic, economic, and institutional barriers influencing equitable access.

Results: The analysis consistently demonstrated a gap between legal access and equitable access across regulatory, clinical, laboratory, and industry perspectives. Although Oklahoma maintains one of the nation’s most accessible medical cannabis programs in terms of legal eligibility, representative barriers included affordability, administrative complexity, transportation limitations, declining caregiver availability, physician participation, federal housing restrictions, and compliance requirements that increase operational costs. Despite differing stakeholder perspectives, all evidence sources consistently identified persistent barriers affecting equitable access for medically vulnerable populations. Collectively, the findings indicate that legal eligibility alone does not ensure equitable access to cannabinoid therapeutics.

Conclusions: Legalization represents an essential first step toward patient access, but legal eligibility alone is an incomplete measure of equitable access. Medical cannabis programs should be evaluated by considering regulatory, structural, geographic, economic, and institutional barriers alongside legal eligibility. These findings support incorporating equity-focused evaluation measures into future medical cannabis policy development and program assessment to improve patient access while maintaining regulatory oversight and patient safety.